As of November 7, 2023, Intercept Pharmaceuticals has a market capitalization of $795 million, indicating its current valuation in the stock market. This figure is a primary metric used to gauge the size of a publicly traded company.
Understanding Intercept Pharmaceuticals' Scale
Intercept Pharmaceuticals, a biopharmaceutical company, is primarily measured by its market capitalization, which reflects the total value of its outstanding shares. This metric provides a snapshot of the company's size and perceived value by investors at a specific point in time.
Key Financial Metrics (as of 07-Nov-2023)
To further illustrate the company's financial standing, here are its key metrics:
| Metric | Value |
|---|---|
| Market Capitalization | $795 million |
| Stock Price | $19.00 |
| Shares Outstanding | 41.8 million |
These figures are derived from its public trading data, as detailed in company profiles such as the Intercept Pharmaceuticals Company Profile on PitchBook.
What Does Market Capitalization Mean?
Market capitalization (or "market cap") is calculated by multiplying the current stock price by the total number of outstanding shares. It represents the total dollar value of a company's equity and is often used by the investment community to rank the size of companies.
- Small-Cap Companies: Typically have a market cap between $300 million and $2 billion.
- Mid-Cap Companies: Usually range from $2 billion to $10 billion.
- Large-Cap Companies: Generally exceed $10 billion.
Based on its $795 million market capitalization, Intercept Pharmaceuticals falls into the small-cap category. This often suggests a company that may be in a growth phase, or operates in a niche market, carrying different risk and return profiles compared to larger, more established corporations. Its size reflects its current valuation within the highly specialized and capital-intensive biopharmaceutical industry.
